Targeting the KRAS G12C Mutation in Patients With Advanced Solid Tumors

  H&O  What is the KRAS G12C mutation? DH RAS mutations are one of the most common mutations in cancer (after the P53 mutation). Estimates suggest […]

Recent Insights Into the Use of Combination Immunotherapy in Solid Tumors

  H&O  What are the main targets of immunotherapy? JL  In solid tumors, immunotherapy currently focuses the most on the checkpoint proteins cytotoxic T-lymphocyte–associated protein 4 […]